CMS identifies Medicare billing codes for combination antibody therapy
The Centers for Medicare & Medicaid Services has identified Healthcare Common Procedure Coding System codes for billing Medicare for the combination monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly and Co.
The Food and Drug Administration this month authorized administering the monoclonal antibodies together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy. The emergency use authorization also authorizes the treatment for patients 65 or older with certain chronic medical conditions.
Related News Articles
Headline
The AHA July 11 released its quarterly Health Care Plan Accountability Update, a roundup of news, letters, statements and other resources covering private…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Centers for Medicare & Medicaid Services July 10 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
The Healthcare Equality Network July 3 sent a letter to the Centers for Medicare & Medicaid Services, expressing concerns about claims denials by…
Headline
The Department of Health and Human Services’ Office of Inspector General last week announced its intent to investigate Medicare Advantage Organizations’ prior…
Headline
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…